Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine for Stress Prophylaxis in Healthy Subjects
NCT04173962Phase 2Completed
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- Aug 2019
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ketamine in major depressive disorder (MDD) and post-traumatic stress disorder (PTSD) (2 arms), sponsored by Icahn School of Medicine at Mount Sinai. Primary endpoint: Profile of Mood States - Bipolar Version Composed-Anxious Subscale at 1 week. Started Aug 2019; status: completed.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT04173962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04173962.